Latest Ratios: P/E Ratio 36.6x · EV/EBITDA 27.6x · ROE 20.6%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $47.2B | $41.6B | $37.9B | $30.6B | $41.5B | $48.3B | $31.9B | $24.1B | $21.1B | $22.2B | $14.3B |
| Enterprise Value | $48.8B | $43.1B | $40.2B | $31.7B | $43.2B | $49.6B | $32.8B | $25.1B | $20.6B | $21.5B | $13.9B |
| P/E Ratio → | 36.60 | 32.03 | 29.42 | 24.67 | 33.10 | 39.97 | 44.39 | 22.48 | 66.79 | 32.40 | 31.12 |
| P/S Ratio | 6.80 | 5.98 | 5.82 | 4.48 | 6.06 | 7.65 | 5.97 | 4.67 | 4.29 | 4.96 | 3.41 |
| P/B Ratio | 7.05 | 6.17 | 6.43 | 5.23 | 7.82 | 8.97 | 6.54 | 5.07 | 4.61 | 4.59 | 3.38 |
| P/FCF | 41.00 | 36.08 | 27.62 | 20.76 | 40.65 | 37.31 | 39.72 | 27.85 | 23.14 | 31.10 | 21.92 |
| P/OCF | 30.30 | 26.66 | 21.66 | 17.27 | 31.63 | 32.56 | 34.58 | 23.59 | 19.37 | 24.95 | 18.08 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.21 | 6.17 | 4.65 | 6.31 | 7.85 | 6.14 | 4.86 | 4.19 | 4.81 | 3.32 |
| EV / EBITDA | 27.62 | 24.41 | 23.02 | 19.58 | 22.34 | 29.73 | 28.40 | 21.30 | 18.50 | 20.39 | 16.18 |
| EV / EBIT | 33.00 | 27.88 | 24.84 | 22.14 | 27.22 | 34.42 | 35.62 | 25.29 | 20.18 | 24.39 | 22.65 |
| EV / FCF | — | 37.44 | 29.25 | 21.53 | 42.33 | 38.27 | 40.86 | 29.03 | 22.65 | 30.17 | 21.33 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.4% | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% | 53.1% | 54.3% | 54.7% | 53.9% | 52.3% |
| Operating Margin | 21.3% | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% | 15.8% | 18.2% | 18.4% | 18.8% | 14.6% |
| Net Profit Margin | 18.8% | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | 13.5% | 20.7% | 6.4% | 15.3% | 10.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.6% | 20.6% | 22.0% | 22.2% | 23.5% | 23.6% | 14.9% | 23.0% | 6.7% | 15.1% | 10.9% |
| ROA | 10.6% | 10.6% | 11.4% | 11.6% | 11.8% | 11.9% | 7.5% | 11.9% | 3.7% | 8.4% | 6.0% |
| ROIC | 13.5% | 13.5% | 14.7% | 14.5% | 17.8% | 16.3% | 11.0% | 14.3% | 16.4% | 15.7% | 12.0% |
| ROCE | 14.5% | 14.5% | 15.6% | 15.1% | 18.3% | 15.7% | 10.9% | 12.8% | 12.4% | 12.0% | 9.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.50 | 0.50 | 0.61 | 0.47 | 0.52 | 0.51 | 0.48 | 0.51 | 0.39 | 0.42 | 0.45 |
| Debt / EBITDA | 1.90 | 1.90 | 2.05 | 1.69 | 1.43 | 1.64 | 2.04 | 2.04 | 1.61 | 1.91 | 2.21 |
| Net Debt / Equity | — | 0.23 | 0.38 | 0.20 | 0.32 | 0.23 | 0.19 | 0.22 | -0.10 | -0.14 | -0.09 |
| Net Debt / EBITDA | 0.89 | 0.89 | 1.29 | 0.71 | 0.89 | 0.75 | 0.80 | 0.87 | -0.40 | -0.63 | -0.45 |
| Debt / FCF | — | 1.36 | 1.64 | 0.78 | 1.68 | 0.96 | 1.14 | 1.18 | -0.49 | -0.94 | -0.59 |
| Interest Coverage | 13.81 | 13.81 | 16.84 | 15.09 | 18.90 | 17.79 | 11.79 | 13.42 | 13.61 | 11.16 | 8.56 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | 1.96 | 2.09 | 2.61 | 2.03 | 2.22 | 2.33 | 1.53 | 3.29 | 3.30 | 3.85 |
| Quick Ratio | 1.52 | 1.52 | 1.57 | 1.97 | 1.47 | 1.74 | 1.84 | 1.21 | 2.74 | 2.85 | 3.28 |
| Cash Ratio | 0.76 | 0.76 | 0.70 | 0.99 | 0.57 | 0.92 | 0.98 | 0.66 | 1.92 | 2.12 | 2.42 |
| Asset Turnover | — | 0.55 | 0.55 | 0.63 | 0.65 | 0.59 | 0.55 | 0.55 | 0.58 | 0.53 | 0.54 |
| Inventory Turnover | 3.22 | 3.22 | 3.00 | 3.27 | 3.01 | 3.51 | 3.48 | 3.47 | 3.49 | 3.59 | 3.76 |
| Days Sales Outstanding | — | 78.12 | 74.23 | 68.96 | 74.89 | 67.70 | 70.96 | 65.75 | 57.64 | 59.09 | 54.81 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.6% | 0.7% | 0.7% | 0.9% | 0.6% | 0.5% | 0.7% | 0.9% | 0.9% | 0.8% | 1.0% |
| Payout Ratio | 21.6% | 21.6% | 21.3% | 21.4% | 19.9% | 19.5% | 30.9% | 19.2% | 60.4% | 24.9% | 32.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.7% | 3.1% | 3.4% | 4.1% | 3.0% | 2.5% | 2.3% | 4.4% | 1.5% | 3.1% | 3.2% |
| FCF Yield | 2.4% | 2.8% | 3.6% | 4.8% | 2.5% | 2.7% | 2.5% | 3.6% | 4.3% | 3.2% | 4.6% |
| Buyback Yield | 0.9% | 1.0% | 3.0% | 1.9% | 2.7% | 1.6% | 1.5% | 3.0% | 2.0% | 0.9% | 3.0% |
| Total Shareholder Yield | 1.5% | 1.7% | 3.8% | 2.7% | 3.3% | 2.1% | 2.2% | 3.9% | 2.9% | 1.6% | 4.1% |
| Shares Outstanding | — | $284M | $291M | $296M | $300M | $307M | $312M | $318M | $325M | $326M | $329M |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying A stock.
Agilent Technologies, Inc.'s current P/E ratio is 36.6x. The historical average is 26.2x. This places it at the 83th percentile of its historical range.
Agilent Technologies, Inc.'s current EV/EBITDA is 27.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.8x.
Agilent Technologies, Inc.'s return on equity (ROE) is 20.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 14.3%.
Based on historical data, Agilent Technologies, Inc. is trading at a P/E of 36.6x. This is at the 83th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Agilent Technologies, Inc.'s current dividend yield is 0.59% with a payout ratio of 21.6%.
Agilent Technologies, Inc. has 52.4% gross margin and 21.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Agilent Technologies, Inc.'s Debt/EBITDA ratio is 1.9x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
China market dependency
Metrics are mathematically derived from official filings.
Premium Valuation Reflects Quality, Not Growth
Agilent's forward P/E of 24.32 and EV/EBITDA of 18.45 appear to price in its high-margin, recurring revenue model rather than aggressive growth, as the PEG ratio of 2.24 suggests the market is paying a significant premium for earnings quality and stability.
The valuation multiples sit at a premium to the peer median, particularly when compared to Thermo Fisher's forward P/E of 34.60 and Danaher's 41.20, but this appears justified by Agilent's superior net margin of 19.3% versus the peer group's range of 14.7% to 21.6%. The PEG ratio of 2.24 indicates the market is not pricing in rapid earnings acceleration, which aligns with the company's positioning as a steady compounder rather than a high-growth disruptor. Investors should monitor whether the premium holds if the cyclical recovery in Biopharma CAPEX, a key driver for the LSAG segment, fails to materialize as expected.
Margin Expansion Driven by Mix Shift
Agilent's gross margin has expanded to 55.5% in 2026Q3, a 310 basis point increase from 2026Q1, suggesting successful execution on pricing and a favorable mix shift toward higher-margin software and service revenues within the CrossLab segment.
The operating margin of 23.6% in the latest quarter represents a significant improvement from the 18.0% trough in 2025Q2, indicating that the company is effectively leveraging its fixed-cost base as revenue recovers. This margin expansion appears to be structural rather than purely cyclical, as the net margin of 19.3% is now approaching the levels of pure-play life science tools peers like Waters Corporation. However, the sustainability of this margin level is contingent on maintaining pricing power in the face of potential commoditization in the gas chromatography market and managing rising specialized labor costs for field engineers.
ROIC Recovery Signals Improved Capital Efficiency
Return on invested capital has recovered to 3.7% in 2026Q3 from a low of 2.8% in 2025Q2, suggesting that the company's recent acquisitions and capital investments are beginning to generate returns as the business cycle turns.
The ROIC trend, while improving, remains below the 4.0% peak seen in 2024Q4 and 2025Q4, indicating that the significant goodwill buildup from recent M&A activity has temporarily diluted returns. The ROE of 5.0% is modest compared to peers like Thermo Fisher's 13.3%, but this is partly a function of Agilent's conservative leverage strategy. The key driver of future ROIC improvement will be the continued shift toward the high-margin, asset-light CrossLab service model, which should enhance capital efficiency over time.
Working Capital Swings Mask Underlying Efficiency
The cash conversion cycle has improved to 127 days in 2026Q3 from 141 days in 2024Q2, driven primarily by a reduction in days inventory outstanding from 128 to 121, suggesting better inventory management despite the lumpy nature of instrument sales.
The improvement in CCC is a positive signal for working capital efficiency, but the volatility in quarterly FCF margins, ranging from 6.4% to 24.3%, indicates that these swings are driven by the timing of large instrument installations and service contract renewals rather than a fundamental change in operational efficiency. The DSO of 73 days has remained relatively stable, suggesting consistent collection practices, while the DPO of 67 days indicates the company is not aggressively stretching supplier payments. Investors should monitor whether the recent improvement in CCC is sustainable or if it represents a temporary benefit from favorable order timing.
Minimal Leverage Provides Strategic Flexibility
Agilent's debt-to-equity ratio of 0.54 in 2026Q3 remains well below the peer median of 0.58, and the interest coverage ratio of 16.31 indicates that debt service is exceptionally comfortable, providing significant financial flexibility for strategic investments.
The conservative leverage profile is a key differentiator, particularly in the current rising rate environment, as it insulates the company from higher financing costs that could impact more leveraged peers. The D/EBITDA ratio of 8.35 appears elevated, but this is largely a function of the company's strong EBITDA generation rather than excessive debt levels. This financial strength provides a substantial buffer against potential cyclical downturns in Biopharma CAPEX and allows management to pursue opportunistic M&A without straining the balance sheet.
The Misapplied Metric: ROIC in an Acquisition-Heavy Model
The most commonly misapplied ratio to Agilent is Return on Invested Capital (ROIC), which currently appears depressed at 3.7% due to the significant goodwill from recent acquisitions, obscuring the underlying cash-generating power of the core business.
Analysts often use ROIC to evaluate capital efficiency, but for a company like Agilent that is actively using M&A to bolt on new technologies, the metric is distorted by the large intangible asset base. A more appropriate alternative is to analyze the return on tangible capital or to adjust ROIC by excluding goodwill, which would provide a clearer picture of the operational returns generated by the core instrument and service businesses. The current ROIC of 3.7% understates the true earning power of the CrossLab segment, which likely generates returns well in excess of the company's weighted average cost of capital.